--- title: "Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug" description: "Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maintenance therapy in patients with unresectable stage III non-small cell lung cance" type: "news" locale: "en" url: "https://longbridge.com/en/news/276016059.md" published_at: "2026-02-15T23:07:14.000Z" --- # Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug > Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maintenance therapy in patients with unresectable stage III non-small cell lung cancer. This approval is based on positive phase III trial results and positions Sino Biopharmaceutical as a strong competitor in China's lung cancer market. The stock currently holds a Hold rating with a price target of HK$7.90. The company focuses on innovative drug development, particularly in oncology, and has a market cap of HK$116.6B. ### President's Day Sale - 70% Off - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Sino Biopharmaceutical ( (HK:1177) ) has issued an update. Sino Biopharmaceutical has secured Chinese regulatory approval for a new indication of its Category 1 innovative PD-L1 inhibitor benmelstobart injection, marketed as Andewei, as maintenance therapy after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer lacking EGFR or ALK alterations. The approval, supported by positive phase III R-ALPS trial data showing significantly prolonged progression-free survival versus placebo and a manageable safety profile, makes benmelstobart the third domestic PD-L1 inhibitor cleared for this setting, strengthening the group’s competitive position in China’s lung cancer market and advancing its strategy to build a diversified oncology pipeline. The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.90 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page. **More about Sino Biopharmaceutical** Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group focused on innovative drug research, development, manufacturing and commercialization, with a strong presence in oncology. The company develops proprietary therapies for the China market, targeting major diseases such as lung cancer with advanced biologic and small-molecule treatments. **YTD Price Performance:** 5.50% **Average Trading Volume:** 62,002,447 **Technical Sentiment Signal:** Buy **Current Market Cap:** HK$116.6B See more data about 1177 stock on TipRanks’ Stock Analysis page. ### Related Stocks - [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md) - [159102.CN - Huaan Hang Seng Biotech ETF](https://longbridge.com/en/quote/159102.CN.md) - [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md) - [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md) - [159506.CN - Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF](https://longbridge.com/en/quote/159506.CN.md) - [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md) - [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md) - [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md) - [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md) - [01177.HK - SINO BIOPHARM](https://longbridge.com/en/quote/01177.HK.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 中国生物制药称，国家药品监督管理局已批准 Benmelstobart 注射液上市 | 中国生物制药表示，国家药品监督管理局已批准 Benmelstobart 注射剂上市 | [Link](https://longbridge.com/en/news/276024005.md) | | 中国生物制药已完成乳腺癌药物三期临床试验的受试者招募 | 中国生物制药完成乳腺癌药物三期临床试验的受试者招募 | [Link](https://longbridge.com/en/news/275387692.md) | | 石药集团获得监管机构的批准以启动药物试验 | 石药集团获得监管批准开始药物试验 | [Link](https://longbridge.com/en/news/276035104.md) | | 石药集团宣布，罗哌卡因长效注射剂已获准在中国开展临床试验 | 石药集团表示，罗哌卡因长效注射剂已获得中国临床试验批准 | [Link](https://longbridge.com/en/news/276051793.md) | | 中国生物制药宣布 Tecotabart Vedotin 用于胃癌的 III 期临床试验已完成患者入组 | 中国生物制药有限公司宣布已成功完成针对 Tecotabart Vedotin (LM-302) 的 III 期注册研究的患者招募，该药物是一种针对 CLDN18.2 的抗体药物偶联物。该研究重点关注 CLDN18.2 阳性的局部晚期或转移性 | [Link](https://longbridge.com/en/news/275237363.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.